Study guide
12.3 Cardiovascular, Antimicrobial & Dialyzable Drug Dosing
BONENT Certified Hemodialysis Nurse CHN
Track your progress as you read
Finished sections get a check mark.
1 Exam Orientation
1.1 Current CHN Exam Facts and Study Strategy
2 Chapter 1: Renal Anatomy, Physiology & CKD Pathophysiology
2.1 Nephron Physiology & Endocrine Functions 2.2 Acute Kidney Injury & Chronic Kidney Disease Staging 2.3 Fluid, Electrolyte & Acid-Base Imbalances in ESRD
3 Chapter 2: CKD-MBD, Uremia & Clinical Manifestations
3.1 CKD-Mineral and Bone Disorder (CKD-MBD) 3.2 Uremic Syndrome & Multi-System Complications 3.3 Dialysis Patient Education & Nutritional Management
4 Individualized Nursing Care
4.1 Nursing Assessment, Planning and Evaluation 4.2 Treatment Records and Safe Handoffs 4.3 Psychosocial Assessment, Counseling and Referral
5 Chapter 3: Principles of Hemodialysis & Dialysate Chemistry
5.1 Transport Mechanisms: Diffusion, Convection & Ultrafiltration 5.2 Dialyzer Characteristics, Membrane Biocompatibility & Flux 5.3 Dialysate Composition & Concentrate Formulations 5.4 Hemodialysis Adequacy: Urea Kinetics, Kt/V & URR
6 Chapter 4: Vascular Access: Fistulas, Grafts & Catheters
6.1 Arteriovenous Fistulas & Arteriovenous Grafts 6.2 Physical Examination, Surveillance & Monitoring of Access 6.3 Central Venous Catheters & CDC Infection Prevention
7 Chapter 5: Cannulation Practice & Access Complications
7.1 Cannulation Techniques: Rope-Ladder, Buttonhole & Needle Sizing 7.2 Vascular Access Stenosis, Thrombosis & Steal Syndrome 7.3 Access Infiltration, Pseudoaneurysms & Hemorrhage Management
8 Chapter 6: Hemodialysis Treatment Delivery & Circuit Monitoring
8.1 Pre-Dialysis Assessment, Target Dry Weight & UFR Limits 8.2 Extracorporeal Circuit Setup, Priming & Safety Alarms 8.3 Anticoagulation Management: Heparin Protocols & Citrate 8.4 Treatment Termination, Hemostasis & Post-Dialysis Assessment
9 Equipment and Laboratory Skills
9.1 Ancillary Equipment and Bedside Safety 9.2 Blood Sampling, Laboratory Trends and Critical Results
10 Chapter 7: Acute Intradialytic Complications & Emergencies
10.1 Intradialytic Hypotension & Muscle Cramping 10.2 Dialysis Disequilibrium Syndrome & Neurological Events 10.3 Dialyzer Reactions & Hypersensitivity (Type A and Type B) 10.4 Critical Emergencies: Air Embolism, Hemolysis & Blood Loss
11 Extended and Acute Treatment
11.1 Sequential UF, Hemofiltration and Hemoperfusion 11.2 Acute Kidney Injury and High-Risk Dialysis Initiation
12 Chapter 8: Nephrology Pharmacology in Hemodialysis
12.1 Anemia Management: ESAs & Intravenous Iron Therapy 12.2 CKD-MBD Pharmacotherapy: Binders, Vitamin D & Calcimimetics 12.3 Cardiovascular, Antimicrobial & Dialyzable Drug Dosing
13 Home and Peritoneal Dialysis
13.1 Home Dialysis Selection and Adult Learning 13.2 Home Setup, Monitoring and Emergency Readiness 13.3 Peritoneal Dialysis Principles and Nursing Care
14 Kidney Transplantation
14.1 Transplant Benefits, Burdens and Modality Counseling 14.2 Transplant Indications, Contraindications and Referral 14.3 Pretransplant Workup and Waiting-List Coordination 14.4 Immunosuppressants, Interactions and Patient Teaching 14.5 Returning to Dialysis After Graft Failure 14.6 New-Graft Monitoring and Urgent Changes
15 Chapter 9: Water Treatment Systems & Dialyzer Reprocessing
15.1 AAMI/ISO Water Treatment Architecture & Components 15.2 Chemical Contaminant Monitoring & Total Chlorine Testing 15.3 Microbiological Standards, Endotoxin Surveillance & Sampling 15.4 Dialyzer Reprocessing Standards, Testing & Germicide Safety
16 Clinical Unit Management
16.1 Evaluating Dialysis Technology and Supplies 16.2 Staffing, Personnel Policies and Standards of Care
17 Chapter 10: Supervision, Administration & Professional Practice
17.1 RN Delegation, Technician Supervision & Nurse Practice Acts 17.2 CMS Conditions for Coverage & Interdisciplinary Care Planning 17.3 Dialysis Unit Infection Control & Environmental Safety 17.4 Quality Improvement (ESRD QIP), Ethics & Palliative Care
18 Professional Development
18.1 Professional Literature, Organizations and Continuing Learning 18.2 Research Design, Implementation and Evidence Interpretation 18.3 Staff Training, Competency and Remediation
19 Environmental Hazards and Emergency Planning
19.1 Chemical Agents, Disinfection and Exposure Control 19.2 Biological Hazards and Occupational Injury Response 19.3 Fire, Threats and Power or Water Interruptions
12.3 Cardiovascular, Antimicrobial & Dialyzable Drug Dosing
Key Takeaways Explain This Topic AI
Drug removal depends on protein binding, distribution volume, membrane and treatment conditions as well as molecular size.
Antihypertensive timing is individualized; blanket pre-HD withholding is unsafe.
Intradialytic vancomycin may be removed by the dialyzer and must follow pharmacy dose/level and infusion-rate protocols.
Digoxin and rapid potassium changes warrant prescriber review of the actual potassium bath.
Last updated: October 2026
Cardiovascular, Antimicrobial & Dialyzable Drug Dosing
Maintenance hemodialysis fundamentally alters the pharmacokinetics and pharmacodynamics of medications. Loss of renal clearance, uremic alterations in hepatic cytochrome P450 metabolism, reduced plasma protein binding, and intermittent extracorporeal clearance complicate therapeutic dosing. The Certified Hemodialysis Nurse plays a critical role in scheduling medication delivery, preventing intradialytic hemodynamic collapse, and managing complex intradialytic antimicrobial infusions.
Determinants of Drug Dialyzability
Whether a drug is removed during hemodialysis depends on the physicochemical properties of the drug and the characteristics of the dialyzer membrane:
Size: Molecular size influences membrane passage, but protein binding and distribution volume can make a small molecule poorly removable. Consult drug-specific dosing evidence for the actual modality.
Plasma Protein Binding : Only the unbound (free) fraction of a drug crosses the dialyzer membrane . Drugs with high plasma protein binding ( > 90 % >90\% > 90% , such as warfarin at > 98 % >98\% > 98% , carvedilol at > 98 % >98\% > 98% , amlodipine at > 95 % >95\% > 95% , and ceftriaxone at 85 % to 95 % 85\%\text{ to }95\% 85% to 95% ) are not dialyzable, as the bulky albumin-drug complex is retained in the blood circuit. Drugs with low protein binding ( < 20 % to 30 % <20\%\text{ to }30\% < 20% to 30% , such as aminoglycosides at < 10 % <10\% < 10% and lisinopril at 0 % 0\% 0% ) are readily dialyzed.
Volume of Distribution ( V d V_d V d ) : V d V_d V d represents the apparent dilution space of a drug:
High V d V_d V d ( > 1.0 to 2.0 L/kg >1.0\text{ to }2.0\text{ L/kg} > 1.0 to 2.0 L/kg ) : The drug is sequestered in lipid reserves, skeletal muscle, or deep intracellular tissue compartments (e.g., digoxin at V d ∼ 5 to 7 L/kg V_d \sim 5\text{ to }7\text{ L/kg} V d ∼ 5 to 7 L/kg , amiodarone at V d > 60 L/kg V_d > 60\text{ L/kg} V d > 60 L/kg , tricyclic antidepressants). Less than 1% to 5% of total body drug resides within the intravascular compartment. Even if the dialyzer rapidly clears intravascular drug, total body stores remain untouched, and a post-dialysis rebound occurs as tissue stores re-equilibrate into plasma. These drugs are non-dialyzable .
Low V d V_d V d ( < 0.5 to 0.7 L/kg <0.5\text{ to }0.7\text{ L/kg} < 0.5 to 0.7 L/kg ) : The drug is confined primarily to extracellular water and plasma (e.g., aminoglycosides at V d ∼ 0.25 L/kg V_d \sim 0.25\text{ L/kg} V d ∼ 0.25 L/kg , cephalosporins). The drug is directly accessible to dialytic removal and is highly dialyzable .
Water vs. Lipid Solubility : Highly water-soluble (hydrophilic) molecules partition into aqueous dialysate; lipophilic molecules distribute into cell membranes and adipose tissues, escaping clearance.
Dialyzer Membrane Characteristics : Membrane surface area, ultrafiltration coefficient ( K u f K_{uf} K u f ), mass transfer area coefficient ( K o A KoA Ko A ), and blood/dialysate flow rates ( Q b , Q d Q_b, Q_d Q b , Q d ) govern solute clearance.
- Cardiovascular Medications in Hemodialysis
- Antihypertensive Timing
Review BP trends, intradialytic symptoms, drug half-life, dialyzability and the patient’s cardiovascular indications. Routine withholding of every antihypertensive is not a universal recommendation. Some patients need a prescriber-directed timing adjustment; others develop harmful predialysis hypertension when doses are omitted. Record the actual last dose and distinguish a missed medication from a deliberately modified plan.
Beta-Blockers: Dialyzable vs. Non-Dialyzable
Metoprolol & Atenolol : Hydrophilic, low protein binding ( < 12 % <12\% < 12% ), and small V d V_d V d . They are moderately to highly dialyzable . If taken before dialysis, they are washed out into dialysate, leaving the patient unprotected against post-dialysis rebound hypertension; if taken post-dialysis, supplemental dosing may be needed.
Labetalol is less readily dialyzed; it is not approximately 98% protein-bound.
Digoxin: Lethal Dialytic Arrhythmia Hazards
Digoxin is indicated for ventricular rate control in atrial fibrillation and heart failure. In ESRD, digoxin elimination half-life extends from 36 hours to 3.5 to 5 days :
Non-Dialyzability : Digoxin has a massive volume of distribution ( V d ∼ 5 to 7 L/kg V_d \sim 5\text{ to }7\text{ L/kg} V d ∼ 5 to 7 L/kg ) due to avid binding to skeletal muscle and myocardial tissues. Less than 3% is removed during a standard four-hour hemodialysis treatment .
Narrow Therapeutic Window : Target serum levels are strictly 0.5 to 0.9 ng/mL 0.5\text{ to }0.9\text{ ng/mL} 0.5 to 0.9 ng/mL . Toxicity occurs above 1.2 to 2.0 ng/mL 1.2\text{ to }2.0\text{ ng/mL} 1.2 to 2.0 ng/mL .
The Hypokalemia-Digoxin Arrhythmia Trigger : Digoxin binds to and inhibits myocardial N a + / K + Na^+/K^+ N a + / K + -ATPase. Potassium competes with digoxin for this binding site. Rapid dialytic potassium removal drops extracellular potassium. Acute hypokalemia ( K + < 3.5 mEq/L K^+ < 3.5\text{ mEq/L} K + < 3.5 mEq/L ) drastically increases digoxin binding to cardiac myocytes, precipitating lethal ventricular arrhythmias (bidirectional ventricular tachycardia, ventricular fibrillation, severe junctional escape rhythms, and complete heart block).
Review the potassium bath and digoxin exposure with the prescriber when the gradient is concerning. Hypokalemia increases toxicity risk, but no universal bath minimum applies to every patient.
Antimicrobial Dosing & Administration Protocols
Infections are a major cause of morbidity and mortality in kidney failure. Antimicrobial administration via the extracorporeal circuit requires precise timing and therapeutic drug monitoring:
1. Vancomycin
Vancomycin is a glycopeptide ( M W ∼ 1 , 449 Da MW \sim 1,449\text{ Da} M W ∼ 1 , 449 Da ) used for methicillin-resistant Staphylococcus aureus (MRSA) and enterococcal infections. While poorly cleared by historical low-flux membranes, modern high-flux polysulfone dialyzers clear approximately 30 % to 40 % 30\%\text{ to }40\% 30% to 40% of circulating vancomycin .
Vancomycin dose and timing follow the pharmacy protocol, weight, membrane removal and measured exposure. Intradialytic dosing can require compensation for removal; infusion duration follows dose and rate limits.
Rationale for Last 60-Minute Infusion : Infusing into the venous return line over the final hour utilizes the high extracorporeal blood flow ( 350 to 450 mL/min 350\text{ to }450\text{ mL/min} 350 to 450 mL/min ) to rapidly dilute the medication, preventing histamine-mediated Vancomycin Infusion Reaction (Red Man Syndrome) , completing the infusion right as treatment terminates, and saving patient chair time.
Monitoring : Pre-dialysis trough levels are drawn from the vascular access before initiating dialysis. The target trough is 15 to 20 mcg/mL 15\text{ to }20\text{ mcg/mL} 15 to 20 mcg/mL for severe infections (bacteremia, endocarditis, osteomyelitis, vascular access sepsis).
2. Cefazolin
Cefazolin is a first-generation cephalosporin ( M W ∼ 454 Da MW \sim 454\text{ Da} M W ∼ 454 Da ) and the first-line treatment for methicillin-sensitive Staphylococcus aureus (MSSA) vascular access bacteremia. It is 80 % 80\% 80% protein bound and cleared moderately by high-flux dialysis. It is administered post-dialysis : 1 to 2 g 1\text{ to }2\text{ g} 1 to 2 g IV into the venous bloodline during rinseback , three times weekly after each dialysis treatment.
3. Aminoglycosides (Gentamicin & Tobramycin)
Aminoglycosides ( M W ∼ 470 Da MW \sim 470\text{ Da} M W ∼ 470 Da ) are small, water-soluble, < 10 % <10\% < 10% protein bound, with a low V d V_d V d ( 0.25 L/kg 0.25\text{ L/kg} 0.25 L/kg ). They are highly dialyzable, with approximately 50 % 50\% 50% of the drug removed in a single four-hour hemodialysis treatment .
Aminoglycoside regimens require specialist dosing and drug levels; both post-HD and selected pre-HD strategies exist.
Pre-dialysis troughs and post-dose peaks are monitored to prevent irreversible ototoxicity , vestibulotoxicity, and destruction of any residual nephron function.
Dialyzability of Common Medications
Medication Primary Class Molecular Weight / Protein Binding Dialyzable? Clinical Nursing Protocol
Lisinopril ACE Inhibitor 405 Da 405\text{ Da} 405 Da / 0 % 0\% 0% bound Yes (Highly) Administer post-dialysis; hold pre-dialysis to prevent hypotension.
Metoprolol Beta-1 Blocker 267 Da 267\text{ Da} 267 Da / 12 % 12\% 12% bound Yes (Moderate) Hold morning of dialysis; administer post-dialysis.
Carvedilol Alpha/Beta Blocker 406 Da 406\text{ Da} 406 Da / > 98 % >98\% > 98% bound No Administer on regular schedule; no supplemental dose needed.
Amlodipine Calcium Channel Blocker 409 Da 409\text{ Da} 409 Da / > 95 % >95\% > 95% bound No Stable hemodynamics; no dialytic removal.
Digoxin Cardiac glycoside Large distribution volume Poorly removed Monitor toxicity risk and individualized potassium prescription
Vancomycin Glycopeptide Removal varies with membrane and treatment High-flux removal is clinically relevant Use individualized dosing, levels and safe infusion rate
Cefazolin 1st Gen Cephalosporin 454 Da 454\text{ Da} 454 Da / 80 % 80\% 80% bound Moderately Administer 1 − 2 g 1-2\text{ g} 1 − 2 g IV post-dialysis during rinseback.
Gentamicin Aminoglycoside 470 Da 470\text{ Da} 470 Da / < 10 % <10\% < 10% bound Yes ( 50 % ~50\% 50% ) Administer post-dialysis; monitor troughs to prevent ototoxicity.
For serious MRSA infection, vancomycin treatment uses exposure monitoring; predialysis levels of approximately 15–20 mg/L may serve as a practical surrogate in HD under the pharmacy protocol. Intradialytic administration can lose drug through the membrane and requires dose review. Infuse vancomycin no faster than the applicable label/protocol, commonly at most 10 mg/min and for at least 60 minutes; 1,500 mg at 10 mg/min requires at least 150 minutes, not one hour. The final dialysis hour does not automatically prevent an infusion reaction. Loading doses depend on weight and the actual protocol rather than a universal two-gram cap. Digoxin risk rises with hypokalemia; flag a concerning potassium gradient and obtain prescription review rather than independently selecting a bath.
Sources checked 2026-10-10: NIDDK HD ; current device and medication instructions govern product-specific details.